Skip to main content
    Z

    Zevra Therapeutics Inc. (ZVRA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $9.25
    +0.17 (+1.87%)

    Market Cap: $540.30M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Zevra Therapeutics Inc. (ZVRA) Earnings: Report Dates and Results

    Updated Nov 3, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Zevra Therapeutics (ZVRA) is expected to report earnings on Mar 8, 2027. In the quarter ended Sep 30, 2026, Zevra Therapeutics reported EPS of $0.18, above the $0.14 estimate. It beat the EPS estimate in 6 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    45%(18/40)
    Avg Surprise
    -4.22%
    Streak
    5 Q

    Upcoming Estimates

    Reports Mar 8, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.19
    Range$0.13 - $0.25
    11 analysts
    Revenue Consensus
    $41.02M
    Range$36.55M - $45.42M
    11 analysts
    Reports May 4, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.27
    Range$0.15 - $0.47
    3 analysts
    EPS RevisionsNo revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$0.24+12.5%
    60d ago$0.30-10.0%
    30d ago$0.30-10.0%
    7d ago$0.30-10.0%
    Current$0.27
    Revenue Consensus
    $41.33M
    Range$33.90M - $51.97M
    5 analysts

    Next Report

    ZVRA has an expected report date of Mar 8, 2027.

    ZVRA Earnings Call

    The latest ZVRA earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, ZVRA beat 18, missed 20 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $37.76M, up 44.9% from $26.06M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.18$0.14$0.13 - $0.21+28.57%BeatN/A32 up, 0 downNov 3, 2026$37.76M
    Jun 30, 2026$0.25$0.08N/A+212.50%BeatN/A32 up, 1 downAug 5, 2026$39.66M
    Mar 31, 2026$0.18$0.08$0.01 - $0.18+125.00%BeatN/A80 up, 2 downMay 6, 2026$36.22M
    Dec 31, 2025$0.19$0.05-$0.01 - $0.07+280.00%BeatN/A41 up, 0 downMar 9, 2026$34.13M
    Sep 30, 2025-$0.01-$0.04-$0.04 - $0.01+75.00%BeatN/A44 up, 0 downNov 5, 2025$26.06M
    Jun 30, 2025-$0.06$1.38-$0.12 - $2.64-104.35%MissN/A82 up, 1 downAug 12, 2025$25.88M
    Mar 31, 2025-$0.06-$0.18-$0.24 - -$0.12+66.67%BeatN/A73 up, 2 downMay 13, 2025$20.40M
    Dec 31, 2024-$0.69-$0.40-$0.54 - -$0.29-73.11%MissN/A71 up, 0 downMar 11, 2025$12.04M
    Sep 30, 2024-$0.69-$0.41-$0.50 - -$0.36-68.29%MissN/A80 up, 0 downNov 12, 2024$3.69M
    Jun 30, 2024-$0.48-$0.44-$0.49 - -$0.31-9.09%MissN/A51 up, 0 downAug 13, 2024$4.45M
    Mar 31, 2024-$0.40-$0.48-$0.51 - -$0.42+16.67%BeatN/A51 up, 0 downMay 8, 2024$3.42M
    Dec 31, 2023-$0.40-$0.27-$0.54 - -$0.04-48.15%MissN/A61 up, 0 downMar 28, 2024$12.92M
    Sep 30, 2023-$0.40-$0.30-$0.38 - -$0.25-33.33%MissN/A40 up, 0 downNov 7, 2023$2.90M
    Jun 30, 2023-$0.15-$0.34N/A+55.88%BeatN/AN/AN/AAug 14, 2023$8.47M
    Mar 31, 2023-$0.34-$0.23N/A-47.83%MissN/AN/AN/AMay 15, 2023$3.18M
    Dec 31, 2022-$0.26-$0.17N/A-52.94%MissN/AN/AN/AMar 7, 2023$2.02M
    Sep 30, 2022-$0.19-$0.10N/A-90.00%MissN/AN/AN/ANov 9, 2022$2.87M
    Jun 30, 2022-$0.70-$0.14N/A-400.00%MissN/AN/AN/AAug 11, 2022$1.30M
    Mar 31, 2022-$0.05-$0.05N/A0.00%In lineN/AN/AN/AMay 12, 2022$3.96M
    Dec 31, 2021-$0.08-$0.07N/A-14.29%MissN/AN/AN/AMar 30, 2022$2.58M
    Sep 30, 2021-$0.05-$0.08N/A+37.50%BeatN/AN/AN/ANov 10, 2021$1.97M
    Jun 30, 2021-$0.40$0.23N/A-273.91%Miss-350.0%N/AN/AAug 12, 2021$11.99M
    Mar 31, 2021-$1.61-$0.17N/A-847.06%MissN/AN/AN/AMay 13, 2021$12.12M
    Dec 31, 2020-$1.07-$0.64N/A-67.19%MissN/AN/AN/AMar 11, 2021$2.37M
    Sep 30, 2020-$0.64-$0.80N/A+20.00%Beat-166.7%N/AN/AOct 29, 2020$1.93M
    Jun 30, 2020$0.16-$0.02N/A+900.00%BeatN/AN/AN/AAug 12, 2020$6.91M
    Mar 31, 2020-$1.92-$1.76N/A-9.09%MissN/AN/AN/AMay 12, 2020$2.09M
    Dec 31, 2019-$0.16-$1.36N/A+88.24%BeatN/AN/AN/AFeb 28, 2020$1.38M
    Sep 30, 2019$0.96-$4.48N/A+121.43%BeatN/AN/AN/ANov 14, 2019$11.46M
    Jun 30, 2019-$5.28-$6.80N/A+22.35%BeatN/AN/AN/AAug 13, 2019N/A
    Mar 31, 2019-$7.36-$7.36N/A0.00%In lineN/AN/AN/AMay 14, 2019N/A
    Dec 31, 2018-$3.20-$7.60N/A+57.89%BeatN/AN/AN/AFeb 28, 2019N/A
    Sep 30, 2018-$13.41-$12.32N/A-8.85%MissN/AN/AN/ANov 8, 2018N/A
    Jun 30, 2018-$10.40-$15.42N/A+32.56%BeatN/AN/AN/AAug 9, 2018N/A
    Mar 31, 2018-$28.32-$11.04N/A-156.52%MissN/AN/AN/AMay 10, 2018N/A
    Dec 31, 2017-$11.52-$10.96N/A-5.11%MissN/AN/AN/AMar 29, 2018N/A
    Sep 30, 2017-$10.88-$10.76N/A-1.12%MissN/AN/AN/ANov 9, 2017N/A
    Jun 30, 2017-$7.04-$10.08N/A+30.16%BeatN/AN/AN/AAug 10, 2017N/A
    Mar 31, 2017-$13.44-$10.24N/A-31.25%MissN/AN/AN/AMay 10, 2017N/A
    Dec 31, 2016-$10.88-$11.15N/A+2.42%BeatN/AN/AN/AMar 9, 2017N/A
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $0.06, a profit after a loss of $2.26 per share the year before. It was -$34.72 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$0.06N/A
    Dec 31, 2024-$2.26N/A
    Dec 31, 2023-$1.29N/A
    Dec 31, 2022-$1.20N/A
    Dec 31, 2021-$2.14N/A
    Dec 31, 2020-$3.47N/A
    Dec 31, 2019-$11.84N/A
    Dec 31, 2018-$55.33N/A
    Dec 31, 2017-$42.88N/A
    Dec 31, 2016-$34.72N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,900 words across 12 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20265,89512
    2026Q1Mar 31, 20264,96211
    2025Q4Dec 31, 20256,78511
    2025Q3Sep 30, 20256,44612
    2025Q2Jun 30, 20254,70812
    2025Q1Mar 31, 20255,8439
    2024Q4Dec 31, 20247,01912
    2024Q3Sep 30, 20246,48911

    2026Q3 Earnings Call

    Opening remarks

    Nichol Ochsner Vice President of Investor Relations and Corporate Communications Thank you, and welcome to those who are joining us. Today, we will provide an overview of our recent accomplishments, followed by a review of our third quarter 2026 financial results. I encourage you to read our financial results news release, which was distributed this afternoon and is available in the Investors section of our website. Before we begin the call, please note that certain information shared today will include forward-looking statements. Actual results may differ materially from those stated or implied by any forward-looking statements due to risks and uncertainties associated with Zevra's business. Forward-looking statements are not promises or guarantees and are inherently subject to risks, uncertainties, and other important factors that may lead to actual results differing materially from the projections made. They should be evaluated together with the Risk Factors section in our most recent quarterly report on Form 10-Q, our annual report on Form 10-K, and our other filings with the SEC. I'm pleased to welcome Zevra's management team members participating in today's call: Neil McFarlane, Zevra's President and Chief Executive Officer; Joshua Schafer, our Chief Commercial Officer; and Justin Renz, our Chief Financial Officer. Now it's my pleasure to hand the call over to Neil.

    Neil McFarlane President and Chief Executive Officer Thank you, Nichol, and welcome to everyone joining our quarterly call this afternoon. Zevra is a purpose-driven company, redefining what is possible and bringing life-changing therapies to people living with rare diseases. In rare disease, the path is complex. The needs are urgent, and the responsibility is significant. The people and families behind these needs are at the heart of what we do every day. Progress with the U.S. launch of MIPLYFFA, the first approved therapy for Niemann-Pick disease Type C, or NPC, reflects the disciplined execution of our strategic plan and the determination, expertise, and commitment of our people. Together, we are building a trusted company with the capabilities and resolve to make a lasting difference. I'm pleased to share that total net revenue for the third quarter was $37.8 million, an increase of 45% compared to the third quarter of 2025, and net U.S. product revenue for MIPLYFFA was $34 million. What we're seeing in the market suggests that it may be just the beginning, particularly as we strengthen our understanding of the NPC community in the United States, where an estimated 900 people are living with NPC, of whom 300 to 350 have been diagnosed. These estimates are derived from a study published in 2021, prior to any approved treatment for NPC. In the third quarter, we received 13 prescription enrollment forms, bringing the cumulative total since launch to 197.

    Frequently Asked Questions About ZVRA

    When is Zevra Therapeutics's next earnings date?

    Zevra Therapeutics's next earnings report is expected for Mar 8, 2027.

    Did ZVRA beat earnings estimates last quarter?

    Yes. Zevra Therapeutics reported EPS of $0.18 for the quarter ended Sep 30, 2026, above the $0.14 estimate, a 28.57% surprise.

    What EPS do analysts expect from ZVRA next quarter?

    The consensus EPS estimate for Zevra Therapeutics for the quarter ending Dec 31, 2026 is $0.19 from 11 analysts, with estimates from $0.13 to $0.25.

    How often does ZVRA beat earnings estimates?

    Zevra Therapeutics beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +76.29%.